Skip to content

13F-HR filed by RA CAPITAL MANAGEMENT, L.P.

RA CAPITAL MANAGEMENT, L.P. filed this 13F-HR for the quarter ended 2017-09-30, filed 2017-11-14, with 27 holding rows worth $1,106,912,000.

Accession
0001144204-17-059064
Filed
2017-11-14
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q3 2017

A holdings report, 27 entries on the cover page, a total value of $1,106,912,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $1,106,912,000 with VALUE read as thousands by filing date, 13F file number 028-12884. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
ASCENDIS PHARMA A/S DKK 1.0 AD04351P101SPONSORED ADR5,580,690$202,300,000thousands by filing date
WAVE LIFE SCIENCES LTD SHSY95308105Stock7,088,651$154,178,000thousands by filing date
AVEXIS INC05366U100COM1,238,181$119,769,000thousands by filing date
BIOHAVEN PHARMACEUTICAL HOLDING11196105COM1,997,278$74,658,000thousands by filing date
ACHILLION PHARMACEUTICALS IN00448Q201COM13,633,220$61,213,000thousands by filing date
IGNYTA INC451731103COM4,106,601$50,717,000thousands by filing date
G1 THERAPEUTICS INC3621LQ109COM2,684,244$49,793,000thousands by filing date
KALA BIO INC COM483119103Stock2,113,236$48,266,000thousands by filing date
MYOVANT SCIENCES LTDG637AM102COMMON STOCK-FO2,830,455$43,787,000thousands by filing date
AVEO PHARMACEUTICALS INC053588109COM11,328,646$41,350,000thousands by filing date
BIOCRYST PHARMACEUTICALS INC COM09058V103Stock6,984,692$36,600,000thousands by filing date
ZOGENIX INC.98978L204Common Stock992,268$34,779,000thousands by filing date
INSMED INC COM PAR $.01457669307Stock722,714$22,556,000thousands by filing date
KADMON HLDGS INC48283N106COM6,666,666$22,333,000thousands by filing date
ACORDA THERAPEUTICS INC00484M106COM900,259$21,291,000thousands by filing date
IMMUNOMEDICS INC452907108COM1,478,742$20,673,000thousands by filing date
RA PHARMACEUTICALS INC74933V108COM1,351,808$19,736,000thousands by filing date
SANGAMO THERAPEUTICS INC800677106COM1,250,000$18,750,000thousands by filing date
DICERNA PHARMACEUTICALS INC253031108COM2,428,571$13,964,000thousands by filing date
AQUINOX PHARMACEUTICALS INC03842B100COM710,682$10,085,000thousands by filing date
CLEMENTIA PHARMACEUTICALS IN185575107COM585,403$9,887,000thousands by filing date
TG THERAPEUTICS INC COM88322Q108Stock700,000$8,295,000thousands by filing date
KRYSTAL BIOTECH INC COM501147102Stock700,000$6,979,000thousands by filing date
VANDA PHARMACEUTICALS INC921659108COM243,971$4,367,000thousands by filing date
KALVISTA PHARMACEUTICALS INC483497103COM591,070$4,350,000thousands by filing date
CHIASMA INC16706W102COM1,396,400$3,561,000thousands by filing date
PROTEON THERAPEUTICS INC74371L109COM1,337,462$2,675,000thousands by filing date

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001144204-17-059064this filing2017-11-14acceptance time not in the bulk data set